Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Share-based Compensation (2020 - 2025)

Journey Medical (DERM) has disclosed Share-based Compensation for 6 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 13.05% year-over-year to $1.9 million, compared with a TTM value of $5.9 million through Sep 2025, up 12.23%, and an annual FY2024 reading of $6.1 million, up 134.0% over the prior year.
  • Share-based Compensation was $1.9 million for Q3 2025 at Journey Medical, up from $1.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.4 million in Q4 2021 and bottomed at $8000.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $1.3 million recorded in 2025.
  • The sharpest move saw Share-based Compensation soared 17875.0% in 2022, then tumbled 63.26% in 2023.
  • Year by year, Share-based Compensation stood at $2.4 million in 2021, then plummeted by 40.62% to $1.4 million in 2022, then crashed by 63.26% to $529000.0 in 2023, then skyrocketed by 160.49% to $1.4 million in 2024, then surged by 34.54% to $1.9 million in 2025.
  • Business Quant data shows Share-based Compensation for DERM at $1.9 million in Q3 2025, $1.3 million in Q2 2025, and $1.3 million in Q1 2025.